Event

CHI's Third Annual Encouraging Development of Therapeutics for Neglected Diseases

March 12, 2012, March 13, 2012 iCal

Time: TBA
Location: Crowne Plaza Philadelphia Downtown Hotel | Philadelphia, PA

This meeting strives to bring together worldwide experts from various organizations, academia, consortia and the life science industry to discuss, brainstorm and discover novel ideas and possibilities for developing therapeutics for neglected tropical diseases.
 

Coverage Includes:
 

• Promising Therapeutic Targets and Strategies
• Case Studies of Successful Collaborations
• Drug Repositioning
• Screening for Novel Therapeutic Possibilities
• Targeting Leishmania
• Open-Access Resources
• Success and Progress in NDs, Including Malaria and TB

Final Agenda:

MONDAY, MARCH 12
Facilitating R&D for Neglected Diseases: Fostering Collaboration and Navigating the Complex Interface among Diverse Stakeholders
Jacqueline B. Fine, Ph.D., CLPTM, Associate Director, Global Outlicensing and Asset Management, Merck Research Laboratories
Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches
Ian Gilbert, Ph.D., Professor, Drug Discovery Unit, University of Dundee
The Future of Industry-PDP Collaborations: Integrating Global Health into New Pharma Business Model?
Jean-Pierre Paccaud, Director, Business Development, Drugs for Neglected Diseases Initiative
Blockade of iNKT Cells as a Therapeutic Strategy for Sickle Cell Disease
Robert Mashal, Ph.D., CEO, Office of the President, NKT Therapeutics
Challenges in the New Drug Discovery for Tuberculosis - A TMC207 Perspective and Update
Anil Koul, Ph.D., Head, Department of Antimicrobial Research, Janssen Research and Development, Johnson and Johnson Pharmaceuticals
Recent Advances in Visceral Leishmania Vaccine Development Using Genetically Altered Live Attenuated Parasites
Hira Nakhasi, Director, Division of Emerging and Transfusion Transmitted Diseases, OBRR/CBER/FDA
Discover New Biologics for Protection Against Infection by Different and New Viruses
Grace Wong, Ph.D., CEO, (former Genentech, Millennium, AstraZeneca and Serono), ActoKine Therapeutics
Partnerships in Neglected Disease Research: A Pharmaceutical Industry Perspective
James R. Brown, M.Sc., Ph.D. Director Computational Biology, Quantitative Sciences, GlaxoSmithKline
Distributed Drug Discovery (D3): Addressing Large Neglected Disease Challenges with Multiple Small-Scale and Open-Access Resources
William L. Scott, Ph.D., Research Professor, Department of Chemistry and Chemical Biology, Indiana University Purdue University Indianapolis (IUPUI)

TUESDAY, MARCH 13

Repurposing Kinase-Targeted Medicinal Chemistry for Neglected Tropical Disease Drug Discovery
Mike Pollastri, Ph.D., Associate Professor, Chemistry & Chemical Biology, Northeastern University
Talk Title to be Announced
Aris Persidis, Ph.D., President, Biovista, Inc.
Drug Repositioning: An Opportunistic Approach to Identifying New Drugs for Malaria?
Julie Lotharius, Ph.D., Associate Director, Translational Medicine, Medicines for Malaria Venture
Repurposing Drug Candidates - Fexinidazole as a Promising Treatment for Visceral Leishmaniasis
Susan Wyllie, Senior Research Associate and Lecturer, Division of Biological Chemistry and Drug Discovery, University of Dundee
Repurposing Drugs for Tropical Diseases: Case Studies and Open-source Screening Initiatives
Curtis R. Chong, M.D., Ph.D., M.Phil., Partners Cancer Care Hematology & Oncology Fellow, Dana Farber, Brigham and Women's Hospital, Massachusetts General Hospital
Focused Breakout Discussions

Topic 1: Clincial Research Software Tools to Enhance Development of Drugs for Neglected Diseases
Moderator: Dean Gittleman, Senior Director, Operations, Target Health, Inc.
• Issues associated with data collection & management in remote locations
• How can available technology be part of the solution?

• How direct data entry and eSource electronic files can mitigate the risk of using paper records
Topic 2: Pricing of Drugs for Neglected Tropical Diseases
Moderator: Jean-Pierre Paccaud, Director, Business Development, Drugs for Neglected Diseases Initiative
• How to engineer mechanisms that would entice the private sector to participate, although knowing that only minimal margins could be made on such products?
• What are considered as "acceptable margins", or price for patients?
• How to take into account local conditions in pricing a product (extended tiered pricing)?
• What other mechanisms would enable the private sector to contribute?
>> View Program Details
>> Register to join us at the Neglected Diseases conference!
>> Stay on to attend the immediately following
Indications Discovery & Drug Repositioning Summit (March 13-14, 2011)

To register and find out more information please visit: https://chidb.com/register/2012/ngl/reg.asp

Back